ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference
06 mars 2025 04h30 HE
|
ITM Isotope Technologies Munich SE
Trial met primary endpoint, demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus Median PFS was 23.9 months on n.c.a....
ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference
25 févr. 2025 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase...
ITM to Present at Raymond James Private Biotech Symposium
18 févr. 2025 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Raymond James Private Biotech...
ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
07 févr. 2025 08h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 7, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35th Annual Healthcare...
ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
28 janv. 2025 05h00 HE
|
ITM Isotope Technologies Munich SE
Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
13 janv. 2025 08h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich / Berlin, Germany, January 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Ariceum Therapeutics (Ariceum), a private biotech...
ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
13 déc. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew...
ITM to Participate in Upcoming Investor Conferences
11 nov. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, November 11, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor...
ITM, TUM und das TUM Universitätsklinikum unterzeichnen eine neue Rahmenvereinbarung zur Entwicklung innovativer radiopharmazeutischer Krebstherapien
24 oct. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Neufahrn / Garching / München, 24. Oktober 2024 – ITM Isotope Technologies Munich SE (ITM), ein führendes radiopharmazeutisches Unternehmen, die Technische Universität München (TUM) und das TUM...
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
24 oct. 2024 05h00 HE
|
ITM Isotope Technologies Munich SE
Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM...